India’s First Dengue Vaccine Qdenga Expected in 2027: How It Works

India’s First Dengue Vaccine Qdenga Expected in 2027: How It Works

India is expected to receive its first dengue vaccine in the first half of 2027 following an agreement between Dr Reddy’s Laboratories and Japan-based Takeda Pharmaceutical to promote and distribute Qdenga. The vaccine has been designed to protect against all four dengue virus serotypes and is expected to become available after completing the required regulatory and market processes.

Qdenga is intended for people aged four to 60 and is administered in two 0.5 ml doses, with the second dose given three months after the first. Unlike some dengue vaccination approaches, it can be administered regardless of whether a person has previously been infected, meaning pre-vaccination dengue testing is not required.

According to clinical trial data cited in the report, Qdenga demonstrated 80.2% efficacy against confirmed dengue infections one year after the second dose. It also showed 90.4% efficacy against dengue-related hospitalisation after 18 months in the study.

India continues to face a substantial dengue burden, particularly during and after the monsoon season when Aedes mosquitoes can multiply in stagnant water. Provisional data cited in the report recorded 1,13,450 dengue cases and 95 deaths in India during 2025.

The vaccine could add another layer to dengue prevention, but vaccination would not replace mosquito-control measures. Eliminating stagnant water, preventing mosquito breeding and reducing exposure to mosquito bites will remain important. Takeda has also said it is working to expand global production capacity to 100 million Qdenga doses annually by 2030.

Prev Article
How Long Does It Take to Lose Muscle After Stopping the Gym?

Related to this topic: